GENVEYOR

GENVEYOR®

Gene conveyor — the conveyor for next-generation medicine.

Schematic of the AccuLNP™ delivery route. 1 — a nucleic-acid LNP, with mRNA, pDNA, siRNA, or circular ssDNA encapsulated in ionizable lipids, meets the cell membrane. 2 — the membrane invaginates and the particle is taken up into an endosome. 3 — the endosome acidifies, the ionizable lipids take on charge and disrupt it, and the RNA or DNA cargo is released into the cytoplasm. Illustration — not measured data.

AccuLNP™ Transfection Kit Series

Delivering superior performance across mRNA · pDNA · siRNA · circular ssDNA

  • ~60 s encapsulation
  • >90% cell viability
  • mRNA · pDNA · siRNA · cssDNA
  • In vivo (preclinical)
Summary comparison of the AccuLNP kit against Lipofectamine and PEI across seven metrics: transfection efficiency, cell viability, payload versatility, primary immune cells, in vivo delivery, targeted delivery, and reproducibility and scalability. AccuLNP is rated highest on every row.

Our Products

In Vitro

In Vivo

Featured Products

Our Service

About us

The platform

AccuLNP™ is built on a library of several hundred proprietary ionizable lipids, optimised by structure–activity relationship. The head group sets pKa and ionisation against pH and drives endosomal escape; the linker controls biodegradation and conformation; the tail governs endosomal-membrane disruption, and branched tails improve escape. Potent mRNA transfection tracks with a lipid pKa of about 6.2–6.4.

Where we work

Hillsborough, New Jersey, USA
LNP co-development (CRO)
Shenzhen, China
GMP manufacturing (CMO)